Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical & Translational Metabolism
Published in: Clinical Reviews in Bone and Mineral Metabolism 2/2014

01-06-2014 | Original Paper

Bone and Muscle Pleiotropy: The Genetics of Associated Traits

Author: Robert D. Blank

Published in: Clinical & Translational Metabolism | Issue 2/2014

Login to get access

Abstract

Bone and muscle mass are highly correlated. In part, this is a consequence of both tissues sharing common genetic determinants. In addition, both tissues are responsive to their mechanical environments. New genetic tools in mice will allow genes of interest to be inactivated in experimentally defined contexts, thus allowing investigators to distinguish direct effects on each tissue from physiological responses to a primary phenotype in the other.
Literature
1.
Frost HM. The Utah paradigm of skeletal physiology: an overview of its insights for bone, cartilage and collagenous tissue organs. J Bone Miner Metab. 2000;18(6):305–16.PubMedCrossRef
2.
Frost HM. From Wolff’s law to the Utah paradigm: insights about bone physiology and its clinical applications. Anat Rec. 2001;262(4):398–419.PubMedCrossRef
3.
Leblanc AD, et al. Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res. 1990;5(8):843–50.PubMedCrossRef
4.
LeBlanc A, et al. Bone mineral and lean tissue loss after long duration space flight. J Musculoskelet Neuronal Interact. 2000;1(2):157–60.
5.
Jiang SD, Dai LY, Jiang LS. Osteoporosis after spinal cord injury. Osteoporos Int. 2006;17(2):180–92.PubMedCrossRef
6.
Jones HH, et al. Humeral hypertrophy in response to exercise. J Bone Joint Surg Am. 1977;59(2):204–8.PubMed
7.
Torrance AG, et al. Noninvasive loading of the rat ulna in vivo induces a strain-related modeling response uncomplicated by trauma or periosteal pressure. Calcif Tissue Int. 1994;54(3):241–7.PubMedCrossRef
8.
Morey-Holton ER, Globus RK. Hindlimb unloading of growing rats: a model for predicting skeletal changes during space flight. Bone. 1998;22(5 Suppl):83S–8S.PubMedCrossRef
9.
Wysocki A, et al. Whole-body vibration therapy for osteoporosis: state of the science. Ann Intern Med. 2011;155(10):680–6 (W206–2013).PubMedCrossRef
10.
11.
Sugiyama T, et al. Bones’ adaptive response to mechanical loading is essentially linear between the low strains associated with disuse and the high strains associated with the lamellar/woven bone transition. J Bone Miner Res. 2012;27(8):1784–93.PubMedCrossRefPubMedCentral
12.
Gong Y, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–23.PubMedCrossRef
13.
14.
Sawakami K, et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006;281(33):23698–711.PubMedCrossRef
15.
Boyden LM, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–21.PubMedCrossRef
16.
Little RD, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11–9.PubMedCrossRefPubMedCentral
17.
Pierroz DD, et al. Deletion of beta-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation. J Bone Miner Res. 2012;27(6):1252–62.PubMedCrossRef
18.
Li J, et al. Parathyroid hormone enhances mechanically induced bone formation, possibly involving L-type voltage-sensitive calcium channels. Endocrinology. 2003;144(4):1226–33.PubMedCrossRef
19.
Sugiyama T, et al. Mechanical loading enhances the anabolic effects of intermittent parathyroid hormone (1–34) on trabecular and cortical bone in mice. Bone. 2008;43(2):238–48.PubMedCrossRef
20.
Akhter MP, et al. Bone response to in vivo mechanical loading in two breeds of mice. Calcif Tissue Int. 1998;63(5):442–9.PubMedCrossRef
21.
Robling AG, Turner CH. Mechanotransduction in bone: genetic effects on mechanosensitivity in mice. Bone. 2002;31(5):562–9.PubMedCrossRef
22.
Kiel DP, et al. Genetic variation at the low-density lipoprotein receptor-related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men. Bone. 2007;40(3):587–96.PubMedCrossRefPubMedCentral
23.
Saless N, et al. Linkage mapping of femoral material properties in a reciprocal intercross of HcB-8 and HcB-23 recombinant mouse strains. Bone. 2010;46(5):1251–9.PubMedCrossRefPubMedCentral
24.
Jepsen KJ, et al. Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragility. Mamm Genome. 2007;18(6–7):492–507.PubMedCrossRefPubMedCentral
25.
Pluijm SM, et al. Determinants of bone mineral density in older men and women: body composition as mediator. J Bone Miner Res. 2001;16(11):2142–51.PubMedCrossRef
26.
Peeters MW, et al. Heritability of somatotype components: a multivariate analysis. Int J Obes (Lond). 2007;31(8):1295–301.CrossRef
27.
MacDougall JD, et al. Effects of strength training and immobilization on human muscle fibres. Eur J Appl Physiol Occup Physiol. 1980;43(1):25–34.PubMedCrossRef
28.
Ahmetov II, Rogozkin VA. Genes, athlete status and training—an overview. Med Sport Sci. 2009;54:43–71.PubMedCrossRef
29.
Karasik D, et al. Bivariate genome-wide linkage analysis of femoral bone traits and leg lean mass: Framingham study. J Bone Miner Res. 2009;24(4):710–8.PubMedCrossRefPubMedCentral
30.
Deng FY, et al. Bivariate whole genome linkage analysis for femoral neck geometric parameters and total body lean mass. J Bone Miner Res. 2007;22(6):808–16.PubMedCrossRef
31.
32.
Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919–28.PubMedCrossRef
33.
Anderson MS, Kunkel LM. The molecular and biochemical basis of Duchenne muscular dystrophy. Trends Biochem Sci. 1992;17(8):289–92.PubMedCrossRef
34.
McDonald DG, et al. Fracture prevalence in Duchenne muscular dystrophy. Dev Med Child Neurol. 2002;44(10):695–8.PubMedCrossRef
35.
Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop. 2000;20(1):71–4.PubMed
36.
Pouwels S, et al. Risk of fracture in patients with muscular dystrophies. Osteoporos Int. 2014;25(2):509–18.
37.
38.
39.
Montgomery E, et al. Muscle-bone interactions in dystrophin-deficient and myostatin-deficient mice. Anat Rec A Discov Mol Cell Evol Biol. 2005;286(1):814–22.PubMedCrossRef
40.
Schuelke M, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350(26):2682–8.PubMedCrossRef
41.
McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83–90.PubMedCrossRef
42.
Marchitelli C, et al. Double muscling in Marchigiana beef breed is caused by a stop codon in the third exon of myostatin gene. Mamm Genome. 2003;14(6):392–5.PubMedCrossRef
43.
Mosher DS, et al. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007;3(5):e79.PubMedCrossRefPubMedCentral
44.
Zimmers TA, et al. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296(5572):1486–8.PubMedCrossRef
45.
Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Dev. 2008;11(4):487–94.
46.
Hamrick MW. Increased bone mineral density in the femora of GDF8 knockout mice. Anat Rec A Discov Mol Cell Evol Biol. 2003;272(1):388–91.PubMedCrossRef
47.
48.
Hamrick MW, et al. Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise. J Bone Miner Res. 2006;21(3):477–83.PubMedCrossRef
49.
Hamrick MW, et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone. 2007;40(6):1544–53.PubMedCrossRefPubMedCentral
50.
Harslof T, et al. Polymorphisms of muscle genes are associated with bone mass and incident osteoporotic fractures in Caucasians. Calcif Tissue Int. 2013;92(5):467–76.PubMedCrossRef
51.
Hamrick MW, et al. Femoral morphology and cross-sectional geometry of adult myostatin-deficient mice. Bone. 2000;27(3):343–9.PubMedCrossRef
52.
Vecchione L, et al. Craniofacial morphology in myostatin-deficient mice. J Dent Res. 2007;86(11):1068–72.PubMedCrossRef
53.
Blank RD. Mouse genetics: breeding strategies and genetic engineering. In: Basow DS, editor. UpToDate. Waltham: Wolters Kluwer; 2012.
54.
Kim JE, Nakashima K, de Crombrugghe B. Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth. Am J Pathol. 2004;165(6):1875–82.PubMedCrossRefPubMedCentral
55.
Kalajzic I, et al. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J Bone Miner Res. 2002;17(1):15–25.PubMedCrossRef
56.
Zhang M, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002;277(46):44005–12.PubMedCrossRef
57.
Lu Y, et al. DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res. 2007;86(4):320–5.PubMedCrossRef
58.
Rodda SJ, McMahon A. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006;133(16):3231–44.PubMedCrossRef
59.
Maes C, Kobayashi T, Kronenberg HM. A novel transgenic mouse model to study the osteoblast lineage in vivo. Ann N Y Acad Sci. 2007;1116:149–64.PubMedCrossRef
60.
61.
Schuler M, et al. Temporally controlled targeted somatic mutagenesis in skeletal muscles of the mouse. Genesis. 2005;41(4):165–70.PubMedCrossRef
62.
Bothe GW, et al. Selective expression of Cre recombinase in skeletal muscle fibers. Genesis. 2000;26(2):165–6.PubMedCrossRef
63.
Chen JC, et al. MyoD-cre transgenic mice: a model for conditional mutagenesis and lineage tracing of skeletal muscle. Genesis. 2005;41(3):116–21.PubMedCrossRef
64.
65.
66.
Metadata
Title
Bone and Muscle Pleiotropy: The Genetics of Associated Traits
Author
Robert D. Blank
Publication date
01-06-2014
Publisher
Springer US
Published in
Clinical & Translational Metabolism / Issue 2/2014
Print ISSN: 1534-8644
Electronic ISSN: 2948-2445
DOI
https://doi.org/10.1007/s12018-014-9159-4

Other articles of this Issue 2/2014

Clinical Reviews in Bone and Mineral Metabolism 2/2014 Go to the issue

Original Paper

The Influence of Muscular Action on Bone Strength Via Exercise

Original Paper

Clinical Outcomes of Impaired Muscle and Bone Interactions

Original Paper

Imaging Mechanical Muscle–Bone Relationships: How to See the Invisible

Original Paper

Physiology of Mechanotransduction: How Do Muscle and Bone “Talk” to One Another?

Introduction

Past, Present and Future of Muscle–Bone Interactions
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits